In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

LeukoSite acquires CytoMed for $19mm in stock

Executive Summary

LeukoSite (cancer, autoimmune, and inflammatory diseases) has agreed to acquire private biotech CytoMed in a cash and stock deal. CytoMed shareholders initially get $19mm in LeukoSite stock.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Payment Includes Stock
    • Payment Includes Cash
    • Full Acquisition
    • Intra-Biotech Deal
    • Includes Earnout

Related Companies